Triangle Insights Group by Valeris ads

BIO International Convention has consistently served as one of the clearest indicators of where biotech innovation and deal-making are heading. This year, Triangle Insights Group Partners, Parker Guse and Sarah Jims will be attending in San Diego, engaging in conversations at the intersection of science, strategy, and commercialization. Over the past several years, the BIO conference window has coincided with the announcement of numerous high-profile partnerships and licensing deals, reinforcing the event's role as a catalyst for collaboration across the industry. We're excited to see what new deals and strategic partnerships emerge this year and what they may signal about the future direction of biotech. Attending BIO 2026? We'd love to connect via the conference app or reach out to us here at the link below.

Policy changes rarely stop where they start. As lawmakers and regulators continue to scrutinize pharmaceutical pricing, the effects are extending far beyond manufacturers and payers. New pressures on PBMs, increasing transparency, and emerging direct-to-patient models are creating ripple effects throughout the healthcare ecosystem. In Part 3 of our foundational policy series, Triangle Insights Group by Valeris explores how pharmaceutical reform efforts are influencing the evolving role of PBMs and accelerating interest in alternative distribution and access models. Authors Matthew Haynes and Megan Thomas examine what these shifts could mean for manufacturers, patients, and the future of market access strategy. 🔗 Read Part 3: https://lnkd.in/ef3TsN8b 📅 Our series continues with additional perspectives designed to build a foundational understanding of the policy forces reshaping the industry and setting the stage for our Policy-Driven PMA Pivot series. 📩 Interested in discussing how these market changes could affect your organization? Connect with our team: https://lnkd.in/eZ6-TWYF #PharmaStrategy #DrugPricing #HealthcarePolicy #MarketAccess #PBM #DirectToPatient #TriangleInsights

The IRA is doing more than introducing Medicare negotiations. It may also be reshaping innovation incentives across the pharmaceutical market. In Part 2 of our foundational policy series, Triangle Insights Group explores how CMS negotiations and orphan drug considerations could accelerate a strategic shift across development and commercialization decisions. As manufacturers assess future exposure to Medicare negotiations, orphan drugs are drawing increased attention because of their unique treatment under IRA policy. Industry observers have raised questions about how these dynamics could influence pipeline prioritization, lifecycle management, and investment strategy going forward. Authors Matthew Haynes and Megan Thomas examine the broader market implications and why these policy interactions matter beyond rare disease alone. 🔗 Read Part 2: https://lnkd.in/etFZ-jNA 📅 Additional installments in this series are coming soon, building toward our broader Policy-Driven PMA Pivot perspective series. 📩 Want to discuss how these policy shifts could affect your organization’s strategy? Connect with our team:https://lnkd.in/eZ6-TWYF #PharmaStrategy #DrugPricing #HealthcarePolicy #MarketAccess #IRA #OrphanDrugs #TriangleInsights

We’re launching a new series from Triangle Insights Group by Valeris designed to break down the core policy changes reshaping the market and what they could mean for manufacturers, payers, and patients. In this first blog, we examine the IRA Part D redesign and the unintended consequences already emerging across pricing, formulary management, patient access, and plan dynamics. Industry observers have noted growing concerns around increased utilization management, higher premiums, and changing access dynamics resulting from the redesign. Authors Matthew Haynes and Megan Thomas explore why understanding these foundational changes is critical before evaluating broader strategic shifts in pricing and market access. 🔗 Read the blog here: https://lnkd.in/e7gFi9bn 📩 Want to discuss what these policy shifts could mean for your organization? Connect with our team: https://lnkd.in/eZ6-TWYF #PharmaStrategy #DrugPricing #HealthcarePolicy #MarketAccess #IRA #TriangleInsights

As the gene therapy landscape continues to evolve, manufacturers face increasing pressure to demonstrate differentiated value to support reimbursement and patient access. In our latest white paper, Sarah Jims, PhD, Torie Broer Lyons, PhD, and Mahima Bhatt explore how unmet need and clinical trial eligibility jointly shape payer access for gene therapies. The paper highlights how the availability of effective non-gene therapy alternatives influences utilization management, reimbursement flexibility, and commercial viability. Through case studies of marketed gene therapies, our team outlines strategic considerations for manufacturers navigating an increasingly competitive and scrutinized market access landscape. 📄 Read the white paper here: https://lnkd.in/evsZkwzs If you’ll be attending the American Society of Gene & Cell Therapy meeting, connect with Sarah through the conference app or schedule time to talk here: https://lnkd.in/eZ6-TWYF #ASGCT2026 #CellAndGeneTherapy #GeneTherapy #Biopharma #LifeSciences #MarketAccess #LifeSciencesConsulting #TriangleInsightsGroup

𝐓𝐡𝐢𝐬 𝐢𝐬𝐧’𝐭 𝐨𝐧𝐞 𝐩𝐨𝐥𝐢𝐜𝐲 𝐜𝐡𝐚𝐧𝐠𝐞. 𝐈𝐭’𝐬 𝐚 𝐬𝐲𝐬𝐭𝐞𝐦 𝐫𝐞𝐬𝐞𝐭. IRA. MFN. Rebate reform. Alternative channels. Individually, each is disruptive. Together, they are redefining how pharma pricing and access strategies must evolve. Triangle Insights Group has brought it all together in the Policy-Driven PMA Pivot Series—a comprehensive look at what’s changing and what comes next. If you’re evaluating your pricing strategy in today’s environment, this is essential reading. 🎯 Heading to Asembia Specialty Pharmacy Summit 2026? Matt Haynes and Megan Thomas will be there and would welcome the opportunity to discuss what these shifts mean for your specific situation. 📩 Let’s talk about how these dynamics apply to your business: https://lnkd.in/eZ6-TWYF #PharmaStrategy #DrugPricing #HealthcarePolicy #MarketAccess #NetPricing #TriangleInsights #Asembia